Tauroursodeoxycholic Acid for Treatment of Primary Biliary Cirrhosis: A Dose-Response Study

Andrea Crosignani, Pier Maria Battezzati, Kenneth D R Setchell, Pietro Invernizzi, Giovanni Covini, Massimo Zuin, Mauro Podda

Research output: Contribution to journalArticlepeer-review


Tauroursodeoxycholic acid, a highly hydrophilic bile acid, may be of therapeutic value for chronic cholestatic liver diseases. We performed a dose-response study on 24 patients with primary biliary cirrhosis who were randomly assigned to receive 500, 1000, or 1500 mg daily of tauroursodeoxycholic acid for six months. Biliary enrichment with ursodeoxycholic acid ranged from 15% to 48% and was not related with the dose. Serum liver enzyme levels decreased significantly after the first month of treatment with all the three doses. No significant difference among the three doses was found, although further reduction over time occurred with 1000 and 1500 mg daily. Plasma total and HDL cholesterol significantly decreased in patients administered the two higher doses. Diarrhea was the only side effect. In conclusion, a dose of about 10 mg/kg body wt/day of tauroursodeoxycholic acid should be used for long-term studies in patients with primary biliary cirrhosis.

Original languageEnglish
Pages (from-to)809-815
Number of pages7
JournalDigestive Diseases and Sciences
Issue number4
Publication statusPublished - 1996


  • Bile acids
  • Chronic cholestasis
  • Primary biliary cirrhosis
  • Tauroursodeoxycholic acid

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Tauroursodeoxycholic Acid for Treatment of Primary Biliary Cirrhosis: A Dose-Response Study'. Together they form a unique fingerprint.

Cite this